CSChad M. Swanson

Chad M. Swanson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chad M. Swanson has a total of 225 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    N6-methyladenosine (m 6 A) RNA modifications control the antiviral response to influenza A virus infection by limiting IFITM2/3 expression

    by Piotr Kwiatkowski, Liudmila A. Mikheeva, Holly Digby, Clément R. Bouton, Hannah Jones, Stuart J. D. Neil, Michelle L. Holland, Chad M. Swanson

    N 6 -methyladenosine (m 6 A) RNA modifications regulate diverse cellular processes, including the response to virus infection. However, how m 6 A controls antiviral gene expression and whether effects on viral replication are due to direct modification of viral RNA or regulation of cellular transcripts remain unclear. Herein, we analysed how m 6 A modifications control the cell-autonomous innate immune response to influenza A virus (IAV) infection. Depletion or inhibition of the m 6 A writer METTL3 or the m 6 A reader YTHDF2 restricts IAV replication. However, using a quantitative method to identify m 6 A sites, we did not detect substantial m 6 A modification of viral RNA. In contrast, many IAV-induced cellular transcripts were m 6 A modified in their coding region, including those that encode pattern recognition receptors and direct antiviral proteins. Inhibition of interferon signalling restored IAV replication after METTL3 inhibition, highlighting that m 6 A controls the antiviral response to infection. METTL3 inhibition increased expression of the paralogous antiviral proteins IFITM2 and IFITM3, which were required for the antiviral activity of the METTL3 inhibitor. We propose that m 6 A modifications regulate the expression of antiviral proteins to limit the magnitude of their induction and balance antiviral activity with maintaining cellular homeostasis.

  • Open Access

    The long isoform of ZAP coordinates multiple enzymes to mediate complete decay of target transcripts

    by Clément R. Bouton, Grega Gimpelj Domjanič, María José Lista, Rui Pedro Galão, Thomas Courty, Piotr Kwiatkowski, Harry D. Wilson, Peter W.S. Hill, Hannah E. Mischo, Anob M. Chakrabarti, et al.


    • 28 April 2026
      • Vol. 45  (5) , 117305

    The long isoform of ZAP coordinates multiple enzymes to mediate complete decay of target transcripts.

    by Clément R Bouton, Grega Gimpelj Domjanič, María José Lista, Rui Pedro Galão, Thomas Courty, Piotr Kwiatkowski, Harry D Wilson, Peter W S Hill, Hannah E Mischo, Anob M Chakrabarti, et al.

    Zinc-finger antiviral protein (ZAP)-mediated RNA decay (ZMD) restricts the replication of viruses containing CpG dinucleotide clusters. However, why ZAP isoforms differ in antiviral activity and how they recruit cofactors to mediate RNA decay is unclear. Therefore, we determined the ordered events of the ZMD pathway. The long ZAP isoform preferentially binds viral RNA and has distinct binding motifs compared to the short isoform. The endoribonuclease KHNYN then cleaves viral RNA at positions of ZAP binding. The 5' cleavage fragment undergoes TUT4/TUT7-mediated 3' uridylation and degradation by DIS3L2. The 3' cleavage fragment is degraded by XRN1. ZAP and TRIM25 interact with KHNYN, TUT7, DIS3L2, and XRN1 in an RNase-resistant manner. Viral infection promotes the interaction between TRIM25 with these enzymes, leading to viral RNA decay while also decreasing the abundance of cellular transcripts. Overall, the long isoform of ZAP recruits key enzymes to assemble an RNA decay complex on viral RNA.


  • Open Access

    KHNYN is a manganese-dependent endoribonuclease required for ZAP-mediated antiviral restriction

    by Rebecca L Youle, Maria Jose Lista, Emma L Brudenell, Bradley Thompson, Clement Bouton, Elizabeth R Morris, Stuart J D Neil, Chad M Swanson, Ian A Taylor

    Zinc finger antiviral protein (ZAP) is a cytoplasmic protein central to host innate immunity to viral infection. ZAP has no intrinsic catalytic activity but inhibits viral replication by binding to CpG dinucleotides in cytoplasmic viral RNA and recruiting other factors to inhibit protein synthesis and target the RNA for degradation. KHNYN is a ZAP-binding protein required for ZAP-restriction of CpG-rich viral genomes. It contains an extended diKH, PIN nuclease, and CUElike domain, each of which are required for ZAP restriction of viral replication. Here, we report a structural, enzymological, and virological study of KHNYN’s essential PIN nuclease domain. Our crystal structure reveals an extended PIN domain (ex-PIN) containing a conserved N-terminal arm region required for domain stability and an active site tetra-Asp motif, which are both required for antiviral activity. Unlike the weak activity recently reported for the PIN domain, we demonstrate that the KHNYN ex-PIN domain is a highly active Mn2+-dependent single-stranded RNA endonuclease that cleaves with a preference for ApC, ApA, and UpA dinucleotides. These observations extend our view of KHNYN antiviral activity and suggest an unforeseen role for activation by manganese ions in the ZAP–KHNYN antiviral response.


  • Open Access

    The long isoform of ZAP coordinates multiple enzymes to mediate complete decay of target transcripts

    by Clément R. Bouton, Grega Gimpelj Domjanič, María José Lista, Rui Pedro Galão, Thomas Courty, Piotr Kwiatkowski, Harry D. Wilson, Peter W. S. Hill, Hannah E. Mischo, Anob M. Chakrabarti, et al.

    SUMMARY: Zinc-finger Antiviral Protein (ZAP)-mediated RNA decay (ZMD) restricts replication of viruses containing CpG dinucleotide clusters. However, why ZAP isoforms differ in antiviral activity and how they recruit cofactors to mediate RNA decay is unclear. Therefore, we determined the ordered events of the ZMD pathway. The long ZAP isoform preferentially binds viral RNA and has distinct binding motifs compared to the short isoform. The endoribonuclease KHNYN then cleaves viral RNA at positions of ZAP binding. The 5’ cleavage fragment undergoes TUT4/TUT7-mediated 3’ uridylation and degradation by DIS3L2. The 3’ cleavage fragment is degraded by XRN1. ZAP and TRIM25 interact with KHNYN, TUT7, DIS3L2 and XRN1 in a RNase-resistant manner. Viral infection promotes the interaction between TRIM25 with these enzymes, leading to viral RNA decay while also decreasing the abundance of cellular transcripts. Overall, the long isoform of ZAP recruits key enzymes to assemble an RNA decay complex on viral RNA.


  • Open Access

    Structural and functional characterization of the extended-diKH domain from the antiviral endoribonuclease KHNYN

    by Rebecca L. Youle, María José Lista, Clement Bouton, Simone Kunzelmann, Harry Wilson, Matthew A. Cottee, Andrew G. Purkiss, Elizabeth R. Morris, Stuart J.D. Neil, Ian A. Taylor, et al.


  • Open Access

    Structural and functional characterization of the KHNYN extended-diKH domain for mediating ZAP antiviral activity

    by Rebecca L Youle, María José Lista, Clement Bouton, Simone Kunzelmann, Harry Wilson, Matthew A Cottee, Andrew G Purkiss, Elizabeth R Morris, Stuart J D Neil, Ian A Taylor, et al.

    Zinc finger antiviral protein (ZAP) binds CpG dinucleotides in viral RNA and targets them for decay. ZAP interacts with several cofactors to form the ZAP antiviral system, including KHNYN, a multidomain endoribonuclease required for ZAP-mediated RNA decay. However, it is unclear how the individual domains in KHNYN contribute to its activity. Here, we demonstrate that the KHNYN amino terminal extended-diKH (ex-diKH) domain is required for antiviral activity and present its crystal structure. The structure belongs to a rare group of KH-containing domains, characterized by a non-canonical arrangement between two type-1 KH modules, with an additional helical bundle. N4BP1 is a KHNYN paralog with an ex-diKH domain that functionally complements the KHNYN ex-diKH domain. Interestingly, the ex-diKH domain structure is present in N4BP1-like proteins in lancelets, which are basal chordates, indicating that it is evolutionarily ancient. While many KH domains demonstrate RNA binding activity, biolayer interferometry and electrophoretic mobility shift assays indicate that the KHNYN ex-diKH domain does not bind RNA. Furthermore, residues required for canonical KH domains to bind RNA are not required for KHNYN antiviral activity. By contrast, an inter-KH domain cleft in KHNYN is a potential protein-protein interaction site and mutations that eliminate arginine salt bridges at the edge of this cleft decrease KHNYN antiviral activity. This suggests that this domain could be a binding site for an unknown KHNYN cofactor.

  • Open Access

    Syn-CpG-Spacer: A Panel web app for synonymous recoding of viral genomes with CpG dinucleotides

    by Aleksander Sulkowski, Clément Bouton, Chad Swanson

    Vertebrate genomes contain lower than expected frequencies of the CpG dinucleotide. Consequently, many vertebrate viruses have evolved to mimic this composition, possibly in order to evade host antiviral defences (Greenbaum et al., 2008). For example, the antiviral protein ZAP binds CpGs in viral single stranded RNA with specific spacing requirements (Gonçalves-Carneiro et al., 2022), though CpGs are also likely depleted in viral genomes due to other selective pressures (Forni et al., 2023). Increasing CpG abundance by synonymous recoding could facilitate attenuation of viruses without compromising their epitope antigenicity by changing non-CpG codons to alternatives containing CpG without changing the overall amino acid sequence (Gonçalves-Carneiro et al., 2022; Le Nouën et al., 2019; Sharp et al., 2023). There are three ways CpGs can be synonymously introduced in codons: at positions 1-2 for arginine (e.g. AGA → CGA), 2-3 for several amino acids (e.g. ACA → ACG), or in a 3-1 split configuration, if a subsequent codon begins with a G (e.g. ATA-GCA → ATC-GCA).

  • Open Access

    Inhibition of human cytomegalovirus replication by interferon alpha can involve multiple anti-viral factors

    by Shabab Chowdhury, Katie A. Latham, Andy C. Tran, Christopher J. Carroll, Richard J. Stanton, Michael P. Weekes, Stuart J. D. Neil, Chad M. Swanson, Blair L. Strang

    The shortcomings of current direct-acting anti-viral therapy against human cytomegalovirus (HCMV) has led to interest in host-directed therapy. Here we re-examine the use of interferon proteins to inhibit HCMV replication utilizing both high and low passage strains of HCMV. Pre-treatment of cells with interferon alpha (IFNα) was required for robust and prolonged inhibition of both low and high passage HCMV strains, with no obvious toxicity, and was associated with an increased anti-viral state in HCMV-infected cells. Pre-treatment of cells with IFNα led to poor expression of HCMV immediate-early proteins from both high and low passage strains, which was associated with the presence of the anti-viral factor SUMO-PML. Inhibition of HCMV replication in the presence of IFNα involving ZAP proteins was HCMV strain-dependent, wherein a high passage HCMV strain was obviously restricted by ZAP and a low passage strain was not. This suggested that strain-specific combinations of anti-viral factors were involved in inhibition of HCMV replication in the presence of IFNα. Overall, this work further supports the development of strategies involving IFNα that may be useful to inhibit HCMV replication and highlights the complexity of the anti-viral response to HCMV in the presence of IFNα.


  • Open Access

    Strain-Dependent Restriction of Human Cytomegalovirus by Zinc Finger Antiviral Proteins

    by Maria Jose Lista, Adam A. Witney, Jenna Nichols, Andrew J. Davison, Harry Wilson, Katie A. Latham, Benjamin J. Ravenhill, Katie Nightingale, Richard J. Stanton, Michael P. Weekes, et al.

    Determining the function of cellular antiviral factors can inform our understanding of virus replication. The zinc finger antiviral protein (ZAP) can inhibit the replication of diverse viruses.